Successful Commercial Exploitation of Digital Pathology for Cancer Education, Biomarker Discovery and Clinical Diagnosis

  • Peter Hamilton (Participant)
  • James Diamond (Participant)
  • Yinhai Wang (Participant)
  • Ching-Wei Wang (Participant)
  • Paul Kelly (Participant)
  • James, Jacqueline (Participant)
  • Dean Fennell (Participant)

Impact: Health Impact, Quality of Life Impact


PathXL Ltd is a global digital pathology software company, founded by Queen’s researchers who successfully commercialised a novel technology for objective evaluation of performance in cancer diagnostics and thereby improved cancer pathology training. The company’s products initially revolutionized the professional training of young pathologists in the UK and Australia. Now products extend to software for tissue biomarker development, precision medicine and biobanking. PathXL Ltd has raised significant venture capital funding to expand its business growing from 2 to 30 people and is now selling a range of world leading digital pathology products for education, biopharmaceutical and diagnostic research and clinical practice across the world.
Impact statusOngoing
Category of impactHealth Impact, Quality of Life Impact